Lente insulin (Vetsulin)

Lente insulin, marketed as Vetsulin in the United States and Caninsulin internationally, is a porcine-derived intermediate-acting insulin that holds FDA approval for the treatment of diabetes mellitus in both dogs and cats. This veterinary-specific insulin formulation represents one of only two insulins officially approved for use in cats, making it an important option in feline diabetes management. The medication contains purified porcine insulin at a concentration of 40 units per milliliter, which differs from most human insulins that are formulated at 100 units per milliliter. This lower concentration allows for more precise dosing in small animal patients and requires the use of U-40 syringes or the VetPen delivery system.

The mechanism of action of lente insulin involves both rapid and extended glucose-lowering effects due to its unique formulation. Vetsulin is an aqueous suspension containing thirty-five percent amorphous (rapidly absorbed) insulin and sixty-five percent crystalline (slowly absorbed) zinc-insulin crystals in a neutral buffer. This combination provides a rapid onset of action from the amorphous component while the crystalline portion extends duration of effect. In cats, the peak activity following subcutaneous injection typically occurs between 1.5 and 8 hours after administration, with an average peak around 4 hours. The duration of action in cats generally ranges from 8 to 12 hours, which is shorter than in dogs and necessitates twice-daily dosing for most feline patients.

Vetsulin is available as a sterile injectable suspension in 10 milliliter vials and 2.7 milliliter cartridges for use with the VetPen insulin delivery device. The cloudy appearance of the suspension is normal and results from the insulin crystals; the vial must be thoroughly shaken or rolled before each use to ensure uniform distribution. Administration requires either U-40 syringes or the VetPen, and using incorrect syringe types can result in serious dosing errors. The medication is given subcutaneously, typically in the scruff area or along the lateral thoracic region, with injection sites rotated to prevent local tissue reactions.

The safety profile of Vetsulin in cats is well-established through years of veterinary use and FDA approval studies. As with all insulin products, the primary risk is hypoglycemia from excessive insulin effect relative to food intake and activity level. Proper dosing, consistent feeding schedules, and regular blood glucose monitoring are essential for safe use. Vetsulin should not be used in cats with known pork allergies, though such allergies are extremely rare in feline patients. The medication provides a reliable option for veterinarians preferring to use a product specifically approved for veterinary use, with the backing of extensive safety and efficacy data in companion animals.

The primary indication for Vetsulin in cats is the treatment of diabetes mellitus, a metabolic disease characterized by chronic hyperglycemia resulting from inadequate insulin production or impaired insulin action. Feline diabetes is a common endocrine disorder, particularly in middle-aged to older cats, with prevalence estimates suggesting approximately 1 in 100 to 1 in 500 cats may be affected. Vetsulin helps restore glucose homeostasis by providing exogenous insulin to facilitate cellular glucose uptake, reducing blood sugar levels and alleviating the clinical signs associated with uncontrolled diabetes including excessive thirst, frequent urination, weight loss, and increased appetite.

Vetsulin effectively addresses the glucose dysregulation underlying feline diabetes through its intermediate-acting insulin activity. After subcutaneous injection, the insulin begins working within approximately 30 minutes to 2 hours, reaches peak effect between 1.5 and 8 hours, and provides glucose-lowering activity for 8 to 12 hours in most cats. This pharmacokinetic profile helps reduce both fasting hyperglycemia and postprandial glucose elevations when the medication is coordinated with feeding times. Clinical studies supporting FDA approval demonstrated that the majority of cats treated with Vetsulin according to label directions achieved improved glycemic control.

While diabetic remission rates may be higher with long-acting insulin analogs such as glargine, Vetsulin can still support remission in some diabetic cats when combined with appropriate dietary management. Studies report remission rates ranging from approximately fifteen to twenty-eight percent in cats treated with porcine lente insulin, with better outcomes associated with early treatment initiation, low-carbohydrate diets, and achieving good glycemic control. For cats that do not achieve remission, Vetsulin provides effective long-term maintenance therapy to control clinical signs and prevent diabetes-related complications.

Vetsulin may be selected for feline diabetes management based on several considerations. As an FDA-approved veterinary product, it provides assurance of quality, consistency, and appropriate regulatory oversight for animal use. The 40 units per milliliter concentration allows for more precise measurement of the small doses typically required in cats compared to 100 units per milliliter human insulins. The availability of the VetPen delivery system offers an alternative to traditional syringes that some owners find easier to use. Additionally, in countries with regulations requiring first-line use of veterinary-registered products, Vetsulin represents a compliant choice for initiating insulin therapy.

Veterinarians may also choose Vetsulin for cats transitioning from other insulin types or when other insulins have not provided adequate glycemic control. Some cats respond better to specific insulin formulations due to individual variations in insulin absorption and metabolism. The twice-daily dosing requirement, while sometimes considered less convenient than once-daily protocols attempted with longer-acting insulins, ensures reliable overlap of insulin activity throughout the day. For cats with variable or unpredictable insulin requirements, the intermediate duration of Vetsulin may offer advantages in allowing more responsive dose adjustments.

The dosing approach for Vetsulin in cats differs from that in dogs, with feline dosing calculated on a per-animal basis rather than strictly by body weight. The recommended initial dose is 1 to 2 units per cat per injection, administered twice daily at approximately twelve-hour intervals. This starting dose applies regardless of the cat's body weight, reflecting the narrower weight range in cats compared to dogs and the general observation that most diabetic cats require similar insulin amounts. The veterinarian will determine the specific starting dose based on the severity of hyperglycemia, clinical signs, and individual patient factors, with more severely affected cats typically starting at the higher end of the recommended range.

Once initiated, Vetsulin dosing requires careful titration based on clinical response and blood glucose monitoring results. Dose adjustments are typically made in 0.5 to 1 unit increments, with changes implemented no more frequently than every one to two weeks to allow assessment of each dose level's effect. The goal is to achieve blood glucose concentrations that eliminate clinical signs of diabetes while avoiding hypoglycemia. Most cats ultimately require doses in the range of 1 to 4 units per injection, though individual requirements vary. Maximum recommended doses should be discussed with the veterinarian, as cats requiring very high doses may have concurrent conditions causing insulin resistance.

The treatment duration for diabetes mellitus is typically lifelong unless the cat achieves diabetic remission. During the initial stabilization period, which may take several weeks to months, frequent monitoring and dose adjustments are necessary. Blood glucose curves, where multiple glucose measurements are taken over 12 to 24 hours, help assess insulin duration and effectiveness. Once stable glycemic control is established, monitoring frequency may decrease but should continue regularly to detect any changes in insulin requirements. Cats that achieve remission should still be monitored for diabetes recurrence.

Proper administration technique is essential for consistent Vetsulin effectiveness. Before each use, the vial must be shaken thoroughly until the suspension appears uniformly milky and cloudy. Failure to adequately mix the insulin can result in inconsistent dosing, as the crystalline and amorphous components may separate. Using either U-40 syringes or the VetPen ensures accurate dose measurement. Subcutaneous injections are given in the dorsal neck or lateral thoracic region, with sites rotated to prevent lipodystrophy. Injections should be administered concurrently with or immediately after meals to coordinate insulin activity with nutrient absorption.

Missed doses require thoughtful management to avoid both hyperglycemia and hypoglycemia. If a dose is missed and recognized within a few hours, the owner may give the dose as directed by the veterinarian. If the next scheduled dose is approaching, it is generally better to skip the missed dose and continue with the regular schedule. Doses should never be doubled. Owners should contact their veterinarian for specific guidance about missed doses and should maintain a treatment log documenting injection times, doses, and any irregularities.

Completing the full treatment protocol as prescribed by the veterinarian is important for achieving optimal diabetes control. Stopping insulin prematurely because symptoms improve can lead to rapid return of hyperglycemia and clinical signs. Conversely, continuing the same dose indefinitely without monitoring may result in either inadequate control or hypoglycemia if the cat's requirements change. Regular veterinary follow-up allows appropriate adjustment of the treatment plan based on the cat's response, supporting the best possible outcome for diabetic feline patients.

Vetsulin demonstrates a favorable safety profile in diabetic cats when used according to label directions with appropriate monitoring. The medication has been extensively evaluated through FDA approval studies and years of clinical veterinary use. Most cats tolerate Vetsulin well, with adverse effects primarily related to the glucose-lowering action of insulin rather than direct toxicity of the medication itself. Understanding and monitoring for these effects is fundamental to safe and effective diabetes management in feline patients.

Hypoglycemia represents the most significant and potentially dangerous side effect of Vetsulin therapy in cats. This occurs when insulin activity exceeds the body's glucose supply, resulting in abnormally low blood sugar levels. Hypoglycemia risk is highest when insulin doses are too high, when cats do not eat adequately, or when there is unexpected variation in insulin absorption or activity. Early signs include weakness, lethargy, stumbling, disorientation, and behavior changes. Severe hypoglycemia can progress to tremors, seizures, collapse, and if untreated, can be life-threatening. Pet owners must be educated to recognize these signs and respond immediately with oral glucose sources such as corn syrup or honey applied to the gums.

Local reactions at injection sites represent another category of potential adverse effects, though these are generally mild. Some cats may experience brief discomfort during injection, temporary swelling, or localized skin changes. Lipodystrophy, characterized by thickening or loss of subcutaneous fat at repeatedly used injection sites, can develop with chronic insulin therapy if injection locations are not adequately rotated. These local effects are minimized through proper injection technique, rotation of sites, and use of appropriately sized needles. Any persistent or concerning injection site reactions should be reported to the veterinarian.

Systemic allergic reactions to Vetsulin are rare but possible. Because Vetsulin contains porcine-derived insulin, cats with pork allergies could theoretically experience allergic responses, though documented cases are extremely uncommon. Signs of allergic reaction might include facial swelling, hives, difficulty breathing, or generalized skin reactions. Any suspected allergic reaction requires immediate veterinary attention and likely discontinuation of the pork-derived insulin in favor of alternative insulin products. Anti-insulin antibody development is possible with any insulin therapy but does not commonly cause clinical problems in cats treated with porcine insulin.

Long-term Vetsulin therapy requires ongoing monitoring for both effectiveness and any emerging adverse effects. Regular blood glucose assessment helps ensure the insulin dose remains appropriate as the cat's condition may change over time. Weight monitoring tracks overall metabolic status and nutritional adequacy. Periodic comprehensive examinations and laboratory testing identify any diabetes-related complications or concurrent conditions that might affect insulin requirements. Open communication between pet owners and the veterinary team ensures that any concerns about the cat's response to treatment are addressed promptly and appropriately.

Vetsulin is contraindicated in cats with known systemic allergy to pork or pork products, as the medication is derived from purified porcine pancreatic tissue. While true pork allergies are extremely rare in cats, any history of allergic reaction to pork-based products warrants caution and consideration of alternative insulin sources. Signs of pork allergy might include gastrointestinal symptoms after consuming pork, skin reactions, or respiratory symptoms. Cats with documented hypersensitivity should receive insulin derived from non-porcine sources, such as human recombinant insulin products.

Administration of Vetsulin during hypoglycemic episodes is absolutely contraindicated. Giving insulin to a cat with already low blood glucose would further reduce sugar levels and potentially cause a life-threatening hypoglycemic crisis. Before each insulin injection, owners should assess their cat's overall status and willingness to eat. If hypoglycemia is suspected based on symptoms such as weakness, lethargy, disorientation, or collapse, insulin should be withheld and appropriate emergency measures taken. Blood glucose measurement, when possible, helps confirm hypoglycemia and guide response.

Certain concurrent medical conditions may affect the safety or appropriateness of Vetsulin therapy in cats. While diabetes frequently coexists with other diseases in older cats, conditions causing significant insulin resistance may require different therapeutic approaches or aggressive dose adjustments. Cats with diabetic ketoacidosis, a serious metabolic emergency, require intensive hospital management that may include short-acting insulin rather than intermediate-acting Vetsulin. Severe concurrent illness, significant infections, or major inflammatory conditions can dramatically affect insulin requirements and glucose regulation, potentially making standard Vetsulin dosing protocols unreliable.

Life stage considerations for Vetsulin in cats include the absence of specific safety data for use in kittens, breeding animals, pregnant cats, or lactating queens. The FDA approval studies and package labeling note that safety and effectiveness have not been established in these populations. While diabetes is uncommon in kittens, reproductive-age cats, and pregnant or nursing queens, treatment decisions for such patients should involve careful veterinary judgment weighing the risks of uncontrolled diabetes against any unknown risks of insulin therapy during these life stages. In most cases, the benefits of treating diabetes would be expected to outweigh potential concerns, but individualized assessment is essential.

Comprehensive medication disclosure to the veterinarian is essential when managing diabetic cats with Vetsulin, as numerous drugs can affect glucose metabolism and insulin effectiveness. Drug interactions with insulin may enhance the risk of hypoglycemia, reduce insulin efficacy, or complicate diabetes management in other ways. This applies to prescription medications, over-the-counter products, supplements, and any treatments the cat receives. Understanding potential interactions allows the veterinary team to adjust monitoring and dosing appropriately.

Multiple medication categories can enhance insulin's glucose-lowering effect and increase hypoglycemia risk. Concurrent use of other antidiabetic medications, including oral hypoglycemics like glipizide or additional insulin products, requires extremely careful coordination to prevent dangerous blood sugar drops. Certain cardiovascular medications including angiotensin-converting enzyme inhibitors and beta-blockers may potentiate insulin effects or mask hypoglycemic symptoms. Beta-blockers are sometimes prescribed for cats with heart conditions and can interfere with the normal physiological responses that would otherwise alert owners to low blood sugar. When such medications are necessary, more intensive glucose monitoring is warranted.

Several drug categories can antagonize insulin action and reduce Vetsulin effectiveness, potentially destabilizing glycemic control. Corticosteroids are powerful insulin antagonists that can dramatically increase blood glucose levels and insulin requirements. Diabetic cats requiring corticosteroid therapy for conditions such as asthma, inflammatory bowel disease, or autoimmune disorders may need substantial insulin dose increases. Progestins and certain reproductive hormones similarly oppose insulin action. Thyroid hormone supplementation in hyperthyroid cats being treated concurrently may affect insulin sensitivity. When these medications are necessary, close collaboration between veterinarian and owner ensures appropriate adjustments to the diabetes management plan.

Monitoring and management strategies when potential drug interactions exist include more frequent blood glucose assessment and willingness to adjust insulin doses based on clinical findings. When potentially interacting medications are initiated or discontinued, increased vigilance for signs of hypoglycemia or hyperglycemia helps detect problems early. The veterinarian may recommend more frequent blood glucose curves during transition periods. Owners should contact the veterinary team whenever new medications are considered, including seemingly benign products, to allow evaluation of potential effects on diabetes management.

General precautions for Vetsulin use in cats emphasize the importance of proper handling, accurate dosing, and consistent monitoring throughout treatment. Vetsulin must be administered exclusively with U-40 syringes or the VetPen delivery system designed for U-40 insulin. Using U-100 syringes with Vetsulin would result in approximately 2.5 times the intended dose, potentially causing severe or fatal hypoglycemia. This critical safety point must be clearly communicated to all household members involved in the cat's care. The vial must be shaken thoroughly before each dose to ensure uniform suspension of the insulin crystals.

Owner education represents a cornerstone of safe Vetsulin therapy. Pet owners must learn proper injection technique, understand the importance of coordinating insulin administration with feeding, recognize signs of hypoglycemia and hyperglycemia, and know how to respond to emergencies. Written instructions reinforcing verbal teaching help ensure owners can reference key information when needed. Emergency supplies including a glucose source such as corn syrup should be readily available in the home. Owners should know when to contact the veterinarian or seek emergency care for their diabetic cat.

Monitoring requirements during Vetsulin therapy are extensive, particularly during the initial stabilization period. Blood glucose curves, performed either at the veterinary clinic or at home, assess insulin duration and effectiveness. Regular measurement of fructosamine provides insight into longer-term glucose control. Clinical monitoring of symptoms, water intake, urine output, body weight, and overall demeanor complements laboratory testing. The frequency of monitoring is highest during the first several weeks of treatment and when dose adjustments are made, then may decrease once stable control is established. However, ongoing periodic monitoring remains important throughout the cat's treatment.

Vetsulin packaging and the veterinary team will provide specific warnings about potential complications. Signs requiring immediate veterinary attention include symptoms of severe hypoglycemia such as seizures or collapse, signs of diabetic ketoacidosis such as vomiting, lethargy, or labored breathing, or any other sudden deterioration in the cat's condition. Owners should not hesitate to contact their veterinarian with concerns, as early intervention often prevents more serious problems.

Special considerations apply to various cat populations receiving Vetsulin. Geriatric cats frequently have concurrent conditions such as chronic kidney disease or hyperthyroidism that affect diabetes management. Cats with renal disease may have altered insulin clearance and variable glucose regulation. Hyperthyroid cats should ideally have their thyroid condition addressed as part of comprehensive diabetes management. Very small cats require particular attention to accurate dosing given the potency of even small amounts of insulin. Individual patient assessment guides appropriate monitoring frequency and treatment adjustments for each diabetic cat.

Proper storage of Vetsulin is essential for maintaining insulin potency and ensuring consistent therapeutic effect. Unopened vials and VetPen cartridges should be stored in the refrigerator at temperatures between 36°F and 46°F (2°C to 8°C). The medication should not be frozen, as freezing destroys insulin activity. If a vial or cartridge accidentally freezes, it should be discarded and replaced. Within the refrigerator, Vetsulin should be placed away from the freezer compartment in a location with stable temperature. Once opened, the vial may be kept refrigerated or stored at room temperature below 77°F (25°C) for up to 42 days according to manufacturer guidelines.

Before each use, Vetsulin must be thoroughly shaken or gently rolled to resuspend the insulin crystals uniformly throughout the solution. The properly mixed suspension should appear uniformly cloudy or milky without clumps, particles, or clear areas. If the insulin appears abnormal after mixing, including any frosted appearance on the vial walls, lumps that won't disperse, or unusual discoloration, the vial should be discarded. Allowing insulin to warm to room temperature before injection may reduce injection site discomfort, though this is not required. The vial should be inspected before each use and discarded if beyond the 42-day in-use period or the expiration date on the label, whichever comes first.

Safe handling practices for Vetsulin extend to proper disposal and prevention of accidental exposure. Used syringes and pen needles should be placed in approved sharps containers and disposed of according to local regulations. Veterinary clinics may accept sharps for disposal, or community pharmaceutical take-back programs may be available. The insulin vial and any unused medication should be disposed of properly when expired or no longer needed. Vetsulin should be kept out of reach of children and other pets. While the U-40 concentration reduces risk compared to U-100 insulins, accidental injection can still cause hypoglycemia requiring medical attention. Anyone experiencing accidental needlestick or injection should monitor for symptoms and seek medical care if needed.

Vetsulin is appropriate for use in diabetic cats of all breeds, with no breed-specific contraindications or documented variations in drug response. Feline diabetes affects cats of all breeds and mixed-breed backgrounds, though certain breed predispositions have been identified in research studies. The effectiveness of Vetsulin depends on individual patient factors including remaining pancreatic function, insulin sensitivity, and overall health status rather than specific breed characteristics.

Some cat breeds demonstrate higher diabetes prevalence, potentially resulting in more frequent need for insulin therapy including Vetsulin. Burmese cats show significantly elevated diabetes risk in some geographic populations, particularly in Australia and Europe, suggesting genetic factors in disease susceptibility. Other breeds with reported increased prevalence in various studies include Tonkinese, Russian Blue, Norwegian Forest, and Abyssinian cats. Domestic shorthair and longhair cats represent the numerical majority of diabetic patients simply due to their overall population numbers. Breed predisposition affects diabetes development but does not predict response to Vetsulin therapy.

Body size variations among cat breeds affect practical aspects of Vetsulin dosing and administration. While feline dosing is given on a per-cat basis rather than strictly by weight, very small cats may require particular attention to accurate dose measurement. Larger breeds such as Maine Coons may need doses at the higher end of typical ranges. Obese cats, regardless of breed, often have significant insulin resistance that can affect initial dosing requirements and may improve with weight loss. The U-40 concentration of Vetsulin provides dosing precision advantages for small patients compared to U-100 insulin products.

Age-related considerations apply across all breeds when using Vetsulin for feline diabetes. The disease most commonly develops in middle-aged to older cats, typically those over seven years old. Senior cats frequently have concurrent conditions such as chronic kidney disease or hyperthyroidism that complicate diabetes management. Younger diabetic cats may be better candidates for aggressive protocols aimed at achieving remission. Very young cats rarely develop diabetes, and when they do, treatment decisions require individualized veterinary assessment. Regardless of age or breed, all diabetic cats benefit from proper diagnosis, appropriate treatment selection, and consistent monitoring throughout their care.

Within the category of veterinary-approved insulins, Vetsulin shares FDA approval status with protamine zinc insulin marketed as ProZinc. These two products represent the only insulin options specifically approved for veterinary use in cats in the United States. ProZinc, a human recombinant protamine zinc insulin at U-40 concentration, offers a longer duration of action than Vetsulin in most cats. Both products are appropriate first-line choices for veterinarians preferring approved veterinary products. The selection between them may depend on individual patient response, dosing convenience considerations, and veterinarian preference based on clinical experience.

Human insulin products used off-label in cats offer additional therapeutic options, particularly the long-acting insulin analogs associated with higher diabetic remission rates. Glargine insulin, marketed as Lantus and available as generic formulations and Basaglar, provides extended duration of action and is considered by many specialists to offer the best chance of diabetic remission when combined with low-carbohydrate diets. Detemir insulin, sold as Levemir, demonstrates similar efficacy to glargine in cats. NPH insulin, while available and inexpensive, has a short duration in cats that limits its practical usefulness. These human products require U-100 syringes and careful attention to concentration differences when transitioning between insulin types.

Complementary approaches to feline diabetes management accompany insulin therapy regardless of the specific product chosen. Dietary management with low-carbohydrate, high-protein diets is considered essential for optimal glycemic control and maximizing remission potential. Weight management through appropriate caloric intake helps improve insulin sensitivity in overweight diabetic cats. Blood glucose monitoring, whether performed at home or in the veterinary clinic, guides dose adjustments and assesses treatment response. Some cats may receive additional medications for concurrent conditions, requiring coordination with diabetes management. Any changes to the treatment protocol, including medication substitutions, should be made only under veterinary guidance to ensure safe and effective diabetes care.